Illumina takes off: Strong Q2 and raised forecast fuel accumulation
Reading Time: 2 minutes
Strong numbers and raised forecast: Illumina significantly exceeds analyst expectations in revenue and profit in Q2 and substantially raises its targets for 2026. Clinical sequencing as a driver for the stock: The record growth in diagnostic consumables and the success of the NovaSeq X platform ensure long-term recurring revenue. Massive buying pressure under high volume: Institutional investors are seizing the operational turnaround for targeted purchases. Illumina is regarded as the undisputed global market leader in DNA sequencing and...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
